A groundbreaking milestone has been reached in the fight against malaria. Novartis announced today that its revolutionary therapy has received regulatory approval to address malaria in newborns and infants, signaling a major advancement in global health. This cutting-edge medicine will now be available for countries where malaria is most prevalent